Immunoscape Raises $14M To Advance Deep Immunomics Platform For High-Dimensional Immune Profiling And Drug Discovery

Apr 14, 2021•over 4 years ago

Amount Raised

$14 Million

Description

ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced it has completed a $14 million fundraising round led by existing investors Anzu Partners, University of Tokyo Edge Capital Partners (UTEC) and new investor EDBI, an investment arm of the Economic Development Board of Singapore. The new round brings ImmunoScape’s total funding in the past year to $25 million.

Company Information

Company

Immuno Scape

About

ImmunoScape is an immunomics-focused company with a technology platform that allows for immune profiling and characterization of the human immune response at extremely high resolution. The company's Deep Immunomics platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, and visualization tools to provide novel, reproducible immune profiling information. This technology has been utilized across multiple therapeutic areas, especially in oncology and infectious disease, both to better understand immunotherapy safety and efficacy and to identify drug targets. For more information, please visit https://immunoscape.com/.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech